<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">Like mRNA vaccines, DNA vaccines generate effective antiviral neutralizing antibodies by activating CD4
 <sup>+</sup> and CD8
 <sup>+</sup> T cells [
 <xref rid="bib171" ref-type="bibr">171</xref>, 
 <xref rid="bib172" ref-type="bibr">172</xref>, 
 <xref rid="bib173" ref-type="bibr">173</xref>]. The DNA drug product is stable for a longer duration and can be deployed in an effective and executable manner [
 <xref rid="bib174" ref-type="bibr">174</xref>]. To meet the large demand to treat patients across the globe, the DNA plasmid manufacture process facilitates the scaled manufacture of the drug [
 <xref rid="bib173" ref-type="bibr">173</xref>, 
 <xref rid="bib174" ref-type="bibr">174</xref>].
</p>
